Literature DB >> 8996836

Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies.

P S Aisen1.   

Abstract

Inflammatory mechanisms in the brain may contribute to the neurodegenerative process in Alzheimer's disease. The cerebral acute-phase response mediated by inflammatory cytokines, the complement cascade, and the accumulation of activated microglial cells are appropriate targets for anti-inflammatory intervention. Pilot studies showed that tolerable doses of prednisone suppress the peripheral acute-phase response in Alzheimer's disease, and a multicenter therapeutic trial of prednisone is in progress. Two other anti-inflammatory drugs, hydroxychloroquine and colchicine, are also under investigation.

Entities:  

Mesh：

Year:  1997        PMID： 8996836     DOI： 10.1159/000213842

Source DB:  PubMed          Journal:  Gerontology        ISSN： 0304-324X            Impact factor:   5.140


  19 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  Triglyceride-rich lipoprotein lipolysis products increase blood-brain barrier transfer coefficient and induce astrocyte lipid droplets and cell stress.

Authors:  Linda L Lee; Hnin H Aung; Dennis W Wilson; Steven E Anderson; John C Rutledge; Jennifer M Rutkowsky
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-11       Impact factor: 4.249

Review 4.  The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?

Authors:  Adriana P Hermida; William M McDonald; Kyle Steenland; Allan Levey
Journal:  Expert Rev Neurother       Date:  2012-11       Impact factor: 4.618

5.  beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis.

Authors:  C K Combs; J C Karlo; S C Kao; G E Landreth
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

6.  Overexpression of mutant amyloid-β protein precursor and presenilin 1 modulates enteric nervous system.

Authors:  Kendra L Puig; Brianna M Lutz; Siri A Urquhart; Andrew A Rebel; Xudong Zhou; Gunjan D Manocha; MaryAnn Sens; Ashok K Tuteja; Norman L Foster; Colin K Combs
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 7.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

8.  Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease.

Authors:  Mei-xia He; Wan-li Yang; Ming-ming Zhang; Ya-jun Lian; Hai-ying Hua; Jin-sheng Zeng; Li-rong Zhang
Journal:  Neurol Sci       Date:  2009-12-03       Impact factor: 3.307

Review 9.  The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.

Authors:  Qingguang Jiang; Michael Heneka; Gary E Landreth
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

Authors:  Jason L Eriksen; Sarah A Sagi; Tawnya E Smith; Sascha Weggen; Pritam Das; D C McLendon; Victor V Ozols; Kevin W Jessing; Kenton H Zavitz; Edward H Koo; Todd E Golde
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.